JOHN KIRKWOOD to Risk Factors
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Risk Factors.
Connection Strength
0.539
-
Multiple primary melanoma in association with other personal and familial cancers. Cancer Med. 2023 02; 12(3):2474-2483.
Score: 0.075
-
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 05; 9(5).
Score: 0.069
-
Indoor tanning exposure in association with multiple primary melanoma. Cancer. 2021 02 15; 127(4):560-568.
Score: 0.067
-
A four-marker signature of TNF-RII, TGF-a, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med. 2014 Jan 23; 12:19.
Score: 0.042
-
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer. 2009 Feb 15; 115(4):859-68.
Score: 0.030
-
Building upon the standard of care in adjuvant therapy of high-risk melanoma. J Clin Oncol. 2005 Dec 01; 23(34):8559-63.
Score: 0.023
-
Melanoma. Cancer Chemother Biol Response Modif. 2005; 22:563-90.
Score: 0.022
-
Melanoma in the older person. Oncology (Williston Park). 2004 Aug; 18(9):1187-96; discussion 1196-7.
Score: 0.022
-
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res. 2023 01 04; 29(1):154-164.
Score: 0.019
-
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol. 2001 Mar 01; 19(5):1430-6.
Score: 0.017
-
Update on the role of adjuvant interferon for high risk melanoma. Forum (Genova). 2000 Jul-Sep; 10(3):230-9.
Score: 0.016
-
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000 Jun; 18(12):2444-58.
Score: 0.016
-
Thick melanoma is associated with low melanoma knowledge and low perceived health competence, but not delays in care. J Am Acad Dermatol. 2020 08; 83(2):587-590.
Score: 0.015
-
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 05; 20(5):701-710.
Score: 0.015
-
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
Score: 0.014
-
Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clin Cancer Res. 2017 Sep 01; 23(17):5034-5043.
Score: 0.013
-
The adjuvant treatment of malignant melanoma. J Fla Med Assoc. 1997 Mar; 84(3):147-52.
Score: 0.013
-
Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncol. 2015 Jan; 16(1):15-7.
Score: 0.011
-
A relation between childhood sun exposure and dysplastic nevus syndrome among patients with nonfamilial melanoma. Epidemiology. 1991 May; 2(3):210-4.
Score: 0.009
-
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010 May 10; 28(14):2452-9.
Score: 0.008
-
Dysplastic nevi in association with multiple primary melanoma. Cancer Res. 1988 Feb 15; 48(4):1016-8.
Score: 0.007
-
Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery. 2007 Mar; 60(3):471-81; discussion 481-2.
Score: 0.006
-
Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol. 2001 Feb 01; 19(3):812-23.
Score: 0.004
-
Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol. 1997 Jun; 15(6):2351-8.
Score: 0.003
-
Recent advances in the care of the patient with malignant melanoma. Ann Surg. 1997 Jan; 225(1):1-14.
Score: 0.003